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 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Although coffee consumption has been associated with reduced
frequency of liver disease, it is unclear whether the effect is from
coffee or caffeine and whether there is an effect on hepatic ﬁbro-
sis speciﬁcally. This study was undertaken to use a food-fre-
quency instrument for dietary caffeine consumption to evaluate
the relationship between caffeine intake and liver ﬁbrosis.
Patients undergoing liver biopsy completed a detailed caffeine
questionnaire on three occasions over a 6-month period. Caffeine
intake was compared between patients with mild and advanced
liver ﬁbrosis (bridging ﬁbrosis/cirrhosis). Logistic regression
was used to evaluate the association between caffeine consump-
tion and hepatic ﬁbrosis. One hundred seventy-seven patients
(99 male, 104 white, 121 with chronic hepatitis C virus [HCV]
infection) undergoing liver biopsy completed the caffeine ques-
tionnaire on up to three occasions. Results from repeated ques-
tionnaires were consistent. Daily caffeine consumption above
the 75th percentile for the cohort (308 mg = approximately 2.25
cups of coffee equivalents) was associated with reduced liver
ﬁbrosis (odds ratio [OR], 0.33; 95% conﬁdence interval [CI],
0.14–0.80; p = 0.015) and the protective association persisted
after controlling for age, sex, race, liver disease, body mass index,
and alcohol intake in all patients (OR, 0.25; 95% CI, 0.09–0.67;
p = 0.006), as well as the subset with HCV infection (OR, 0.19;
95% CI, 0.05–0.66; p = 0.009). Despite a modest trend, consump-
tion of caffeine from sources other than coffee or decaffeinated
coffee was not associated with reduced liver ﬁbrosis. A reliable
tool for measurement of caffeine consumption demonstrated that
caffeine consumption, particularly from regular coffee, above aJournal of Hepatology 20
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Caffeine is the most widely used drug in the world and the
most common caffeine delivery vehicle is coffee. Additional vehi-
cles for caffeine delivery include carbonated soft drinks and
‘‘energy drinks.” Interestingly, high doses of caffeine are banned
from competitive sports as a performance enhancing drug, caf-
feine is included in a number of over-the-counter pain relievers
and there are at least four psychiatric diagnoses associated with
caffeine use. Thus, it comes as quite a surprise to most people
that drinking coffee is associated with diminished mortality
and that protection from death due to liver disease is the best
documented contributor to reduced mortality. Although caffeine
is the most extensively characterized pharmacologic agent in cof-
fee, there are other active agents as well, and it has been difﬁcult
to capitalize on the hepatoprotective qualities of coffee without
knowing which ingredient mediates the protective effect.
The recent demonstration by Modi and colleagues [1] that caf-
feine appears to protect from severe liver ﬁbrosis in a case control
study of patients seen at the NIH for treatment of chronic liver
disease, primarily hepatitis C, offers at least a partial explanation
for the protective effects of coffee. In their study Modi and co-
workers observed that patients who consumed more than the
75th percentile of caffeine for the cohort (about 300 mg/day
which is equivalent to the caffeine found in 2.25 cups of coffee)
were signiﬁcantly less likely to have severe hepatic ﬁbrosis as
deﬁned by Ishak stage P3 (OR 0.33). Evidence for a protective
effect of caffeine persisted even after correction for age, sex, race,
type of liver disease, body mass index, and alcohol ingestion (OR
0.25); and the protective effect was no less marked in the
patients with HCV infection (OR 0.19). Although prior work had
suggested that other agents (kahwol and cafestol) found in coffee
might afford protection from hepatic ﬁbrosis by altering the
expression of hepatic enzymes involved in activation of agents
(e.g. CCl4) that cause ﬁbrosis in animals [2], the authors were
unaware of prior work indicating the direct effects of caffeine
on hepatic ﬁbrosis in vivo. In this series, coffee was the greatest
single source of caffeine and other sources contributed far less
caffeine. Because coffee was the dominant source of caffeine in
this group of patients, there was only a trend towards an impact
for the contribution of other sources of caffeine toward the pro-
tection from ﬁbrosis.
The pharmacologic properties of caffeine have been explored
for many years and a variety of different pharmacologic mecha-
nisms have been ascribed to caffeine. The most well known and
better understood pharmacologic effect of caffeine is the antago-
nism of adenosine receptors. Adenosine receptors were ﬁrst10 vol. 53 j 207–208
Fig. 1. Adenosine, generated primarily extracellularly from adenine nucleo-
tides, stimulates hepatic ﬁbrosis via A2A receptors on hepatocytes and stellate
cells. Caffeine reduces ﬁbrosis by blocking adenosine A2A receptors.
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clear that there are four different types of adenosine receptors
(A1, A2A, A2B and A3), all of which are members of the G protein
coupled family of receptors [4]. Adenosine receptors are ubiqui-
tous in their expression and they regulate a large number of
physiologic functions.
Adenosine is a short-lived but abundant purine nucleoside
that is released as a result of adenine nucleotide catabolism.
Although hypoxia is the most well known stimulus for increasing
extracellular adenosine levels, it has long been acknowledged
that other types of cellular injury also induce adenosine release
as adenine nucleotides are turned over and released. In the liver,
adenosine is released as a result of the exposure to toxins, includ-
ing ethanol and the hepatic ﬁbrosing agents CCl4 and thioaceta-
mide [5]. Recent work from our laboratory has demonstrated
that adenosine and its receptors (A1 and A2B receptors) play a
central role in the development of hepatic steatosis in mice that
chronically ingest high doses of ethanol [6]. In prior work, we and
others have used a combination of speciﬁc adenosine receptor
antagonists and adenosine receptor knockout mice to demon-
strate a critical role for adenosine A2A receptors in murine models
of hepatic ﬁbrogenesis [5,7]. Indeed, caffeine itself prevented
hepatic ﬁbrosis in response to CCl4 and thioacetamide by, pre-
sumably, blocking adenosine receptor-mediated ﬁbrosis [7].
Adenosine A2A receptors are expressed in hepatic stellate cells
and hepatocytes where they directly stimulate collagen produc-
tion and induce activation of TGFb and stimulate CTGF produc-
tion by hepatocytes [8–10]. Interestingly, all four adenosine
receptors are expressed in human liver and the expression of
adenosine A2A and A2B receptors is markedly increased in cir-
rhotic and steatotic livers [6].
Thus, the demonstration by Modi and colleagues [1] that caf-
feine ingestion prevents advanced liver ﬁbrosis provides further
supportive evidence for a role for adenosine receptors in hepatic
ﬁbrosis. Moreover, these ﬁndings suggest that more selective208 Journal of Hepatology 201adenosine receptor antagonists with more favorable pharmacoki-
netics might offer even greater protection from the development
of hepatic ﬁbrosis and cirrhosis (Fig. 1).Disclosures
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